Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: Initial results

Investigative Radiology

Volumn 48, Issue 5, 2013, Pages 273-279

  Beiderwellen, Karsten J ^a   Poeppel, Thorsten D ^a   Hartung Knemeyer, Verena ^a   Buchbender, Christian ^b   Kuehl, Hilmar ^a   Bockisch, Andreas ^a   Lauenstein, Thomas C ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

68Ga DOTATOC; gastroenteropancreatic NET; PET CT; PET MRI

Indexed keywords

GALLIUM 68; TETRAXETAN;

ADULT; AGED; ARTICLE; BONE LESION; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DATA ANALYSIS; DESCRIPTIVE RESEARCH; DIFFUSION WEIGHTED IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER INJURY; LUNG METASTASIS; LYMPH NODE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEUROENDOCRINE TUMOR; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; WHOLE BODY IMAGING;

EID: 84876295689     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182871a7f     Document Type: Article

References (30)

1. Barakat M. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11:1-18.
2. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
3. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655-2664.
4. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med. 2008;49:1735-1738.
5. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-R73.
6. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
7. Kumar R, Sharma P, Garg P, et al. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol. 2011; 21:2408-2416.
8. Poeppel TD, Binse I, Petersenn S, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864-1870.
9. Ruf J, Schiefer J, Furth C, et al. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med. 2011; 52:697-704.
10. Ruf J, Heuck F, Schiefer J, et al. Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuro-endocrinology. 2010;91:101-109.
11. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintig-raphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23:70-78.
12. Sankowski AJ, Cwikla JB, Nowicki ML, et al. The clinical value of MRI using single-shot echoplanar DWI to identify liver involvement in patients with advanced gastroenteropancreatic-neuroendocrine tumors (GEP-NETs), compared to FSE T2 and FFE T1 weighted image after i.v. Gd-EOB-DTPA contrast enhancement. Med Sci Monit. 2012;18:MT33-MT40.
13. Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: intraindividual comparison of gadoxetic acid-enhanced MRI at 3.0 and 1.5 T. Invest Radiol. 2011;46:383-389.
14. Kim YK, Lee MW, Lee WJ, et al. Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis Invest Radiol. 2012;47:159-166.
15. Motosugi U, Ichikawa T, Onohara K, et al. Distinguishing hepatic metastasis from hemangioma using gadoxetic acid-enhanced magnetic resonance imaging. Invest Radiol. 2011;46:359-365.
16. Schreiter NF, Nogami M, Steffen I, et al. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol. 2012;22:458-467.
17. Zhernosekov KP, Filosofov DV, Baum RP, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007;48:1741-1748.
18. Martinez-Möller A, Souvatzoglou M, Delso G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520-526.
19. Boy C, Heusner TA, Poeppel TD, et al. 68Ga-DOTATOC PET/CT and somato-statin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging. 2011;38:1224-1236.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
21. Hofmann M, Pichler B, Schölkopf B, et al. Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging. 2009;36(suppl 1):S93-S104.
22. Samarin A, Burger C, Wollenweber SD, et al. PET/MR imaging of bone lesionsVimplications for PET quantification from imperfect attenuation correction. Eur J Nucl Med Mol Imaging. 2012;39:1154-1160.
23. Schreiter NF, Brenner W, Nogami M, et al. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging entero-pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39: 72-82.
24. Ruf J. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT in Germany: two sides of two different coins. Eur J Nucl Med Mol Imaging. 2012;39:723-724.
25. Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50:1214-1221.
26. Donati OF, Hany TF, Reiner CS, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med. 2010;51:692-699.
27. Ruf J, Lopez Hänninen E, Böhmig M, et al. Impact of FDG-PET/MRI image fusion on the detection of pancreatic cancer. Pancreatology. 2006;6:512-519.
28. Donati OF, Reiner CS, Hany TF, et al. 18F-FDG-PET and MRI in patients with malignancies of the liver and pancreas. Accuracy of retrospective multi-modality image registration by using the CT-component of PET/CT. Nuklearmedizin. 2010;49:106-114.
29. Kiefer A, Kuwert T, Hahn D, et al. Anatomical accuracy of abdominal lesion localization. Retrospective automatic rigid image registration between FDG-PET and MRI. Nuklearmedizin. 2011;50:147-154.
30. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003;290: 3199-3206.